How India Exports Allopurinol to the World

Allopurinol, a xanthine oxidase inhibitor used primarily for the treatment of gout and hyperuricemia, has a well-established presence in the U.S. pharmaceutical market. According to the FDA's Orange Book, numerous Abbreviated New Drug Applications (ANDAs) for allopurinol have been approved, indicating a competitive generic landscape. The most recent approval was granted in January 2026, reflecting ongoing interest and investment in this therapeutic area.

The regulatory pathway for allopurinol involves the submission of an ANDA, which requires demonstrating bioequivalence to the reference listed drug without the need for extensive clinical trials. This streamlined process facilitates the entry of multiple generic manufacturers into the market. Notably, our data indicates that 223 Indian exporters are actively involved in the allopurinol trade, underscoring India's significant role in supplying this medication to the U.S.

In the European Union, allopurinol is subject to marketing authorization by the European Medicines Agency (EMA). A notable development occurred in July 2020 when the marketing authorization for Duzallo, a combination of allopurinol and lesinurad, was withdrawn at the request of the marketing authorization holder due to commercial reasons. This withdrawal does not affect the availability of allopurinol monotherapy, which continues to be marketed and prescribed across EU member states.

The United Kingdom, following its departure from the EU, maintains its own regulatory framework through the Medicines and Healthcare products Regulatory Agency (MHRA). Allopurinol remains an approved medication in the UK, adhering to stringent EU Good Manufacturing Practice (GMP) requirements to ensure product quality and patient safety.

Allopurinol is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its critical role in treating conditions like gout and hyperuricemia. The medication is recognized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality standards globally.

In India, allopurinol is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on allopurinol, allowing market dynamics to determine its pricing. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

Allopurinol's primary patents have long expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive environment has contributed to its widespread availability and affordability, benefiting patients globally.

In March 2025, the NPPA conducted a review of essential medicines pricing, reaffirming that allopurinol would remain exempt from price controls, thereby maintaining its market-driven pricing structure.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List, resulting in the inclusion of allopurinol in the 24th edition, published in September 2025. This inclusion highlights the drug's continued importance in global health.

In January 2026, the FDA approved a new generic version of allopurinol, further enhancing the competitive landscape and potentially reducing costs for consumers.

In February 2026, the EMA issued updated guidelines on the manufacturing of active pharmaceutical ingredients (APIs), emphasizing stricter quality controls. This development is particularly relevant for Indian exporters, given their significant role in supplying allopurinol to the European market.

In March 2026, the CDSCO announced plans to implement more rigorous inspections of pharmaceutical manufacturing facilities, aiming to ensure compliance with international quality standards. This initiative is expected to impact allopurinol manufacturers and exporters, reinforcing the importance of maintaining high-quality production practices.

India's pharmaceutical industry, including the production of Allopurinol, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API imports originate from China, underscoring a significant dependency on Chinese suppliers for essential raw materials.

This reliance exposes the supply chain to vulnerabilities, as disruptions in China's production or export activities can directly impact India's pharmaceutical manufacturing capabilities. For instance, in February 2024, regulatory actions by the U.S. Food and Drug Administration (FDA) highlighted quality concerns at API manufacturing facilities in both China and India, emphasizing the risks associated with this dependency.

Our proprietary trade data from 2022 to 2026 reveals a high concentration among Allopurinol exporters in India. The top five exporters—IPCA Laboratories Limited, Unichem Laboratories Limited, Indoco Remedies Limited, Sandoz Private Limited, and Par Formulations Private Limited—account for 96.2% of total exports. Notably, IPCA Laboratories Limited alone holds a 35.5% share, indicating a significant single-source risk.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic production of APIs and KSMs. While this initiative has led to the establishment of new manufacturing facilities, the industry continues to face challenges in reducing its dependence on Chinese imports.

Recent geopolitical tensions have further strained the pharmaceutical supply chain. In March 2026, the closure of the Strait of Hormuz due to escalating conflicts disrupted global shipping routes, affecting the transportation of pharmaceuticals from India. This blockade led to increased shipping costs and delays, impacting the timely delivery of essential medicines.

Additionally, the U.S.-China trade tensions have introduced uncertainties in the supply of raw materials, as tariffs and export restrictions can lead to price volatility and supply disruptions. These geopolitical factors underscore the need for a resilient and diversified supply chain to ensure the uninterrupted availability of critical medications like Allopurinol.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source, thereby enhancing supply chain resilience.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to invest in domestic manufacturing of APIs and KSMs, decreasing reliance on imports.

• Strengthen Quality Control: Implement stringent quality assurance protocols to address regulatory concerns and ensure compliance with international standards.

• Develop Alternative Shipping Routes: Establish contingency plans for logistics, including alternative shipping routes and modes of transportation, to mitigate the impact of geopolitical disruptions.

• Monitor Geopolitical Developments: Stay informed about international relations and trade policies to proactively address potential risks affecting the supply chain.

RISK_LEVEL: HIGH